Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445286 | 0.94 | NOTUM (0.45) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24721104 | 0.93 | NPSR1 (0.45) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24721029 | 0.93 | NPSR1 (0.45) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24721143 | 0.93 | NPSR1 (0.45) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1102007 | 0.88 | ALDH1A1 (0.48) | NOTUMALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9315735 | 0.85 | NOTUM (0.51) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21677078 | 0.85 | NOTUM (0.47) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19163454 | 0.85 | NOTUM (0.47) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21095412 | 0.85 | NPSR1 (0.49) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9668715 | 0.85 | NOTUM (0.47) | NOTUMALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024092116-A1 | COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-6420363-B1 | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6291508-B1 | POTENT ABILITY TO BIND TO RETINOIC ACID RECEPTORS THUS USEFUL IN TREATING PSORIASIS AND RHEUMATOID ARTHRITIS. | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6133283-A | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6030964-A | BINDS TO RETINOIC ACID RECEPTORS AND USEFUL FOR TREATING PSORIASIS, AUTOIMMUNE DISEASES, TUMORS, RHEUMATOID ARTHRITIS AND FOR INDUCING IMMUNOSUPPRESSION IN ORGAN TRANSPLANTATION | EISAI CO., LTD. (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5977125-A | Mono-or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0790228-A1 | MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | NOTUM 590/4885ALDH1A1 348/4885MEN1 740/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | NOTUM 63/4885ALDH1A1 1173/4885MEN1 4405/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | NOTUM 3428/4885ALDH1A1 3182/4885MEN1 1372/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NOTUM 4116/4885ALDH1A1 3472/4885MEN1 4729/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | NOTUM 1667/4885ALDH1A1 37/4885MEN1 2431/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | NOTUM 4058/4885ALDH1A1 3208/4885MEN1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.